Histamine exerts its physiological functions through its four receptor subtypes. In this work, we report the subcellular localization of histamine receptor 2 (H2R), a G protein-coupled receptor (GPCR), which is expressed in a wide variety of cell and tissue types. A growing number of GPCRs have been shown to be localized in the nucleus and contribute toward transcriptional regulation. In this study, for the first time, we demonstrate the nuclear localization of H2R in lymphatic endothelial cells. In the presence of its ligand, we show significant upregulation of H2R nuclear translocation kinetics. Using fluorescently tagged histamine, we explored H2R-histamine binding interaction, which exhibits a critical role in this translocation event. Altogether, our results highlight the previously unrecognized nuclear localization pattern of H2R. At the same time, H2R as a GPCR imparts many unresolved questions, such as the functional relevance of this localization, and whether H2R can contribute directly to transcriptional regulation and can affect lymphatic specific gene expression. H2R blockers are commonly used medications that recently have shown significant side effects. Therefore, it is imperative to understand the precise molecular mechanism of H2R biology. In this aspect, our present data shed new light on the unexplored H2R signaling mechanisms. This article has an associated First Person interview with the first author of the paper.
Keratinocytes, once viewed as inert epidermal scaffolds, are now recognized as active participants in the cutaneous immunity. They orchestrate local immune responses by releasing cytokines, chemokines, and alarmins that shape innate and adaptive inflammation. Dysregulated keratinocyte-immune interactions underline chronic inflammatory skin disorders, such as atopic dermatitis, psoriasis, and cutaneous lupus erythematosus. More recently, keratinocytes have been identified as key contributors to secondary lymphedema, a chronic inflammatory and fibrotic condition historically attributed to lymphatic dysfunction. This review revises our understanding of keratinocytes as immunomodulatory cells, while focusing primarily on their emerging role in the pathogenesis of secondary lymphedema. We highlight and appraise recent evidence that lymphatic stasis reprograms keratinocyte differentiation, induces type 2 helper T cells-skewed inflammatory responses, and perpetuates chronic inflammation and fibrosis. Understanding this keratinocyte-immune-lymphatic axis may unveil novel therapeutic targets beyond traditional lymphangiogenic approaches.
1 June 2026 in Clinical and Translational Medicine
Background: Secondary lymphedema is a common complication of cancer treatment and epidermal changes are recognised as histological hallmarks of secondary lymphedema; however, the role of keratinocytes in the pathophysiology of this disease remains unclear. Methods: Hyperkeratosis, up‐regulation of protease‐activated receptor 2 (PAR2) and Th2‐inducing cytokines were assessed in biopsy specimens from patients with unilateral breast cancer‐related lymphedema (BCRL) and in a mouse model of lymphedema. PAR2 inhibition using global PAR2 knockout, keratinocyte‐specific PAR2 KO and bone marrow chimera models, or keratinocyte proliferation inhibition using a topical formulation of Teriflunomide (TF), was analysed in mouse models of lymphedema. We also assessed the direct effects of patient‐derived lymphedema lymph fluid (LF) on keratinocyte activation in vitro. Results: Hyperkeratosis, expression of Th2‐inducing cytokines and PAR2 were significantly increased in BCRL patient biopsies and mouse models. Keratinocytes play a primary role in the lymphedema development by producing T helper 2 (Th2)‐inducing cytokines. Specifically, keratinocyte proliferation and PAR2 expression are early responses following lymphatic injury and regulate the expression of Th2‐inducing cytokines, the migration of Langerhans cells and the infiltration of Th2‐differentiated T cells into the skin. Deficiency of PAR2 or topical inhibition of thymic stromal lymphopoietin rescues secondary lymphedema by reducing Th2 inflammation. Inhibition of PAR2 activation with a small‐molecule inhibitor, or the proliferation of the inhibitor TF, prevents activation of keratinocytes stimulated with lymphedema fluid. Finally, topical TF is highly effective in reducing swelling, fibrosis and inflammation and the overall pathology of lymphedema. Conclusions: Our findings suggest that lymphedema is a chronic inflammatory skin disease, and topically targeting keratinocyte inhibition may be a clinically effective therapy for this condition. Key points: Activated keratinocytes play a key role in the pathophysiology of secondary lymphedema through PAR2 by producing Th2‐inducing cytokines that modulate skin inflammatory responses.